Hannah Slater

The FDA approved avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

The associate director for Patient Outcomes in the Oncology Center of Excellence at the FDA spoke about the new pilot program and how it could aid patients and providers moving forward.

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

The trial is evaluating tisotumab vedotin administered every 3 weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer.

Excluding unassisted attempts to quit smoking, approved medications were more likely to be utilized than other cessation methods in this study, demonstrating a strong correlation with successful quit attempts.

The FDA approved pembrolizumab for IV injection for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.

Combining tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non-small cell lung cancer.

The FDA approved phesgo for injection under the skin to treat adult patients with early and metastatic HER2-positive breast cancer.

Patients enrolled in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.

A survey of patients in Germany found that this patient population needs efficient counseling, as well as a standardized surveillance program to help increase adherence and psychological coping.

The director of Molecular Pathology and assistant professor of Pathology at Cedars-Sinai spoke about the use of NGS testing to match patients with targeted therapy.

Tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non-small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

The updated findings indicated that alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non-small cell lung cancer.

A study of patients in the pandemic epicenter found that the outcome of COVID-19 is worse among those with cancer and will have a lasting impact on those undergoing treatment.

The new website platform will include patient-reported data from clinical trials, capturing relevant information about disease- or treatment-related symptoms.

The FDA approved pembrolizumab for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

In comparison to those who had no history of cancer, an elevated presence of mental health problems was observed among adult cancer survivors in this study.

The FDA’s decision was based on a quality assessment of a new good manufacturing practice (GMP)-certified batch that was successfully manufactured for the lacutamab clinical development program.

This study is the first of its kind to report modest, promising clinical activity with tipifarnib in this patient population.

The FDA is set to review a supplemental new drug application for ibrutinib in combination with rituximab for the treatment of Waldenström’s macroglobulinemia.

Though steroids currently remain the standard frontline treatment for patients with immune thrombocytopenia, second-line treatment options for this patient population are rapidly expanding.

A study presented at the AACR Virtual Annual Meeting II indicated that Hispanics are diagnosed with blood cancers at a significantly younger age than non-Hispanic white individuals.

The FDA approved oral selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least 2 lines of systemic therapy.

In this examination of 102 patients with lung cancer and COVID-19, researchers found that COVID-19 is associated with high burden of severity in this patient population.

The study met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumors had PTEN loss.

Principia Biopharma announced positive data on the durability of response from an ongoing phase 1/2 trial of the investigational treatment in patients with immune thrombocytopenia.

The expert from the American Cancer Society spoke about updated guidelines published recently regarding recommendations on diet and physical activity for cancer prevention.

The combination demonstrated a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of individuals with early triple-negative breast cancer, regardless of PD-L1 expression.

The FDA approved tazemetostat for adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as for adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.

Researchers identified a correlation between the timing of genomic testing and mortality risk in a clinicogenomic cohort of patients with cancer.